Dual Inhibition of PARP and Akt Induces Metabolic Collapse and Apoptosis in Breast Cancer Cells
These findings indicate that the combination of olaparib and capivasterib is a promising therapeutic strategy for breast cancer. Furthermore, evaluation of in vivo toxicity and antitumor effectiveness is essential to validate its potential.
Authors
- Arshi Arshi (ORCID: https://orcid.org/0009-0004-3156-8819)
- Eszter Vámos (ORCID: https://orcid.org/0000-0003-0622-442X)
- Geofrey Ouma Maloba (ORCID: https://orcid.org/0000-0002-1510-8394)
- Ferenc Gallyas (ORCID: https://orcid.org/0000-0002-1906-4333)
- Hamid Ahmadi (ORCID: https://orcid.org/0000-0001-6641-2460)
- Nasreldeen Mohamed Karshom Adam (ORCID: https://orcid.org/0009-0005-2982-1042)
Institutions
- University of Pecs (HU)
Publication Details
- Journal
- Cancers
- Published
- 2025-11-29
- DOI
- https://doi.org/10.3390/cancers17233828
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tempus Közalapítvány
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap